Provenge, an experimental vaccine to treat advanced prostate cancer, "significantly prolonged" men's lives in a recent clinical trial, drugmaker Dendreon reports. The company did not reveal the results of the trial of 512 men, saying they would be given at a Urology conference in late April. These results are a follow-up to the U.S. Food and Drug Administration's 2007 request to see long-term data on the safety and effectiveness of Provenge before final approval.
Read moreMost patients who have prostate cancer are diagnosed with early-stage disease that is localized to the prostate. These patients are able... Read more »
After robotic prostate surgery that is performed for cancer, the patient will have a foley catheter (a small drain that is placed in the... Read more »
The U.S. Food and Drug Administration (FDA) has approved the prostate cancer vaccine Provenge. Provenge does not cure cancer, but it has been shown... Read more »
A new animal study suggests that a strain of the measles virus may treat prostate cancer. Researchers at the Mayo Clinic found that a strain of the... Read more »
In a new study, the experimental cancer vaccine Provenge boosted the three-year survival of patients with advanced prostate cancer by 38 percent... Read more »
Source: ADAM Encyclopedia
In 2010, the FDA approved the chemotherapy drug cabazitaxel (Jevtana) for patients whose condition has worsened during or after treatment with... Read more »
Source: ADAM Encyclopedia
Hormone Therapy and ChemotherapyAndrogen Deprivation Therapy (Hormone Therapy)Male hormones (called androgens), particularly testosterone and... Read more »